Broadcast of EMA-ECDC joint meeting on antimicrobial resistance

The European Medicines Agency (EMA) is organising a joint meeting with the European Centre for Disease Prevention and Control (ECDC) to discuss antimicrobial resistance.The event will take place at EMA’s premises in London on 19 September 2017 and will be broadcast live on the EMA website.

You can access the notice announcing the event here.

You can access the broadcast here.

This meeting will bring together representatives of the World Health Organization (WHO), the European Commission, the European Union (EU) Member States, patients’ and consumers’ organisations, healthcare professionals’ organisations and academia. 

A report on the meeting will be published on the EMA website in due course.

Meet NAREB partners at ETPN2017, 17-19 October 2017

The 12th annual event of the European Technology Platform on Nanomedicine (ETPN) will be held in Torremolinos (Malaga), Spain on 17-19 Octber 2017.

It will be an opportunity to meet several of  NAREB's partners.

Some of the topics of the event:

  • Currents trends in nanomedicine from bench to bedside
  • Focus on translation tools
  • Quality by design
  • Interfacing KETs for healthcare

Deadline for abstract submisison is September 20th (poster and Pitch me up sessions)!

For more information, please consult the conference website here.

NanoTube: a series of videos on nanotechnologies

NanoDiode, a CSA funded by the European Union under the NMP Cooperation FP7 Work Programme, produced NanoTube, a collection of short videoclips, interviewing specialists around Europe working with nanotechnologies.

Do you want to know how physicists, chemists, toxicologists, philosophers, artists, sociologists, industrials and policy makers think nanotechnologies will impact society? Then check the videoclips here and you will hear about their hopes, dreams, expectations, fears and concerns.

FDA issues final guidance for antibacterial streamlined program

FDA published guidance for companies developing new antibacterial drugs. The guideline presents possible streamlined development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need, including patients who have a serious bacterial disease for which effective antibacterial drugs are limited or lacking.

Candidates for a streamlined program include, among others, products with an affed inhibitor that neutralize resistance or an alteration in molecule structure that limits reistance.

For more details, guidance are available here.

The new EU One Health Action Plan against Antimicrobial Resistance

In June 2017, the European Commission adopted the new EU One Health Action Plan against AMR. 

The key objectives of this new plan are built on 3 main pillars:

  1. Making the EU a best practice region
  2. Boosting research, development and innovation
  3. Shaping the global agenda

The Commission has also adopted the 1st deliverable of the plan, i.e., the EU Guidelines on the prudent use of antimicrobials in human health.

More information and documents can be found here.


The NAREB project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 604237.